DOI

10.3390/cells10051100

Date of this Version

5-4-2021

Keywords

glycosylation, N-glycan, immune receptor, immune checkpoint therapy, cancer

Abstract

Evading host immune surveillance is one of the hallmarks of cancer. Immune checkpoint therapy, which aims to eliminate cancer progression by reprogramming the antitumor immune response, currently occupies a solid position in the rapidly expanding arsenal of cancer therapy. As most immune checkpoints are membrane glycoproteins, mounting attention is drawn to asking how protein glycosylation affects immune function. The answers to this fundamental question will stimulate the rational development of future cancer diagnostics and therapeutic strategies.

Comments

This is the publisher PDF of Sun, R.; Kim, A.M.J.; Lim, S.-O. Glycosylation of Immune Receptors in Cancer. Cells 2021, 10, 1100. This article is distributed under a CC-BY license, and is available at DOI: 10.3390/cells10051100.

Included in

Pharmacology Commons

Share

COinS